Last checked at 30 Aug 2022 11:29
30 August 2022
ImmuPharma plc
("ImmuPharma" or the "Company")
Exercise of Options
ImmuPharma plc (LSE : IMM), the specialist drug discovery and development company, announces that L1 Capital Global Opportunities Master Fund ("L1") has exercised Options over 2,000,000 new ordinary shares of 1p each ("Ordinary Shares") at an exercise price of 5p per share, for a consideration of £100,000.
New Ordinary Shares and Admission
The New Ordinary Shares have been allotted today and are issued credited as fully paid and will rank pari passu in all respects with the Company's existing issued ordinary shares.
An application will be made for the New Ordinary Shares to be admitted to trading on the AIM market ("Admission") of the London Stock Exchange. It is anticipated that Admission will occur on or around Monday 5 September 2022.
The New Ordinary Shares represent 0.61% of the Company's enlarged issued share capital.
Total Shares in Issue
For the purposes of the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority ("DTR"), the Board of ImmuPharma hereby notifies the market that following Admission, the Company's total issued share capital will consist of 330,403,115 Ordinary Shares with a nominal value of 1p each.
This figure may be used by Shareholders as the denominator for the calculations by which they may determine if they are required to notify their interest in, or a change to their interest in, the Company under the DTR.
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Alora Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor™ to fund a new international Phase 3 trial for Lupuzor™ and commercialise in the US.
For additional information about ImmuPharma please visit www.immupharma.com. ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.